Pentoxifylline prevents spontaneous brain ischemia in stroke-prone rats

J Pharmacol Exp Ther. 2004 Sep;310(3):890-5. doi: 10.1124/jpet.104.067090. Epub 2004 Jun 16.

Abstract

Anti-inflammatory properties of pentoxifylline (PTX) have recently been described. Spontaneously hypertensive stroke-prone rats (SHRSP) constitute an animal model that develops an inflammatory condition that precedes the appearance of brain abnormalities. The aim of the present investigation was to assess: 1) the efficacy of PTX treatment in protecting the neural system in SHRSP, and 2) how its anti-inflammatory properties might be involved in this effect. Male SHRSP fed with a permissive diet received no drug or PTX (100 or 200 mg/kg/day). Brain abnormalities detected by magnetic resonance imaging developed spontaneously in control rats after 42 +/- 3 days, whereas in rats treated with 100 mg/kg/day PTX, abnormalities developed in only 80% of the animals and only after 70 to 80 days. Treatment with a higher dose of PTX (200 mg/kg/day) completely protected the brain from abnormal development. The drug treatment prevented the accumulation of macrophages or CD4+ positive cells, the activation of glia in brain tissues, and the appearance of inflammatory proteins and thiobarbituric acid-reactive substances in body fluids. PTX treatment did induce a greater increase of serum tumor necrosis factor-alpha (TNF-alpha), but not of interleukin (IL)-1beta and IL-6 induced by in vivo administration of lipopolysaccharide (LPS), which suggests a protective role for TNF-alpha. PTX also exerted protective effects when it was administered after the first occurrence of proteinuria (>40 mg/day). These data indicate that PTX treatment dose-dependently prevents the occurrence of spontaneous brain damage by reducing inflammatory events. We also hypothesize that the increase of TNF-alpha by PTX treatment represents a protective mechanism in SHRSP.

MeSH terms

  • Animals
  • Brain Ischemia / complications*
  • Brain Ischemia / etiology
  • Brain Ischemia / prevention & control*
  • Disease Models, Animal
  • Inflammation / etiology
  • Male
  • Pentoxifylline / therapeutic use*
  • Proteinuria / etiology
  • Proteinuria / metabolism
  • Rats
  • Rats, Inbred SHR
  • Stroke / complications*
  • Vasodilator Agents

Substances

  • Vasodilator Agents
  • Pentoxifylline